Advicenne appoints Board Observer Dr André Ulmann as Interim CEO

– FRANCE, Nîmes –  Advicenne (EPA: ADVIC), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for orphan renal and neurological diseases, today announced that Dr Luc-André Granier has left his role as CEO of the Company and that the Board of Directors has elected Dr André Ulmann, current Board Observer of the company, as Interim CEO of Advicenne, effective immediately.